A summary of the research appears in the journal Developmental Cell on Oct. 27. The mystery of the gene, TEM5, began in 2000 with research conducted by Brad St. Croix, Ph.D., working in the laboratory of Bert Vogelstein, M.D., a Howard Hughes Medical Institute investigator and the Clayton Professor of Oncology, and Kenneth Kinzler, Ph.D., professor of oncology at the Johns Hopkins University School of Medicine…
“We’re living at a time where the aging population is growing,” said Ryan O’Connell, D.Phil., assistant professor of pathology, whose lab made the discovery. …
This switch is driven by p53, the well-documented tumor-suppressing protein. The UNC researchers showed that increasing the level of p53 in scar-forming cells significantly reduced scarring and improved heart function after heart attack. The finding, which was published today in the journal Nature, shows that it is possible to limit the damage wrought by heart attacks, which strike nearly one million people in the United States each year. Heart disease accounts for one in four deaths every year…
In a paper published today in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs. The new drug works by stopping a key process that allows cancer cells to multiply…
CLIP2 serves as a radiation marker: After exposure to radiation from radioiodine, both the genetic activity and the protein expression are increased, as the scientists’ studies were able to substantiate. CLIP2 appears to be particularly significant in the development of tumours in the thyroid gland after radiation exposure…
In an effort to solve this mystery, neuroscientists at The University of Texas Health Science Center at Houston (UTHealth) conducted an experiment in an animal memory model and their results point to a possible explanation. Findings appeared in The Journal of Neuroscience. In the study involving a sea snail that shares many of the same memory mechanisms as humans and a drug used to treat a variety of cancers, the scientists identified memory mechanisms blocked by the drug. …
In an effort to solve this mystery, neuroscientists at The University of Texas Health Science Center at Houston (UTHealth) conducted an experiment in an animal memory model and their results point to a possible explanation. Findings appeared in The Journal of Neuroscience. In the study involving a sea snail that shares many of the same memory mechanisms as humans and a drug used to treat a variety of cancers, the scientists identified memory mechanisms blocked by the drug. Then, they were able to counteract or unblock the mechanisms by administering another agent. …
They used the platform to identify a novel antibody that is undergoing further investigation as a potential treatment for breast, ovarian and other cancers. In research published online in the Proceedings of the National Academy of Sciences, researchers in the lab of Stephen Weiss at the U-M Life Sciences Institute detail an approach that replicates the native environment of cancer cells and increases the likelihood that drugs effective against the growth of tumor cells in test tube models will also stop cancer from growing in humans. The researchers have used their method to identify an antibody that stops breast cancer tumor growth in animal models, and they are investigating the antibody as a potential treatment in humans. “Discovering new targets for cancer therapeutics is a long and tedious undertaking, and identifying and developing a potential drug to specifically hit that target without harming healthy cells is a daunting task,” Weiss said. …
Researchers led by LMU’s Professor Angelika Vollmar and Professor Stephan Sieber of the Technische Universit�t M�nchen have identified a class of chemicals that represent a potential new weapon in the fight against malignant tumors. The compound is itself non-toxic, but it stimulates the killing of rapidly dividing cells by chemotherapeutic drugs. …
The discovery has led to human trials for pancreatic cancer, even in advance of its publication today in the journal Cell. By attacking a wound repair mechanism called fibrosis, the findings may also have implications for other tough-to-treat tumors, such as lung, kidney and liver cancer…